



psych

an Open Access Journal by MDPI

Current Pharmacological Trials Addressing Unmet Needs of Patients with Schizophrenia

Guest Editors:

Dr. Margarita A. Morozova

Research Center of Mental
Health, 115522 Moscow, Russia

Dr. Denis Burminskiy

Research Center of Mental
Health, 115522 Moscow, Russia

Deadline for manuscript
submissions:

closed (25 August 2023)

Message from the Guest Editors

Age-related problems in the treatment of patients with schizophrenia are the next unmet need. Today, psychiatrists have better skills to diagnose schizophrenia early in childhood and to provide patients with better help throughout their life. Due to this, psychiatrists face new issues in terms of adjusting treatment to age-related problems and dealing with comorbid conditions, e.g., aging patients with schizophrenia and dementia. New pharmacological agents can solve a number of these problems.

What can we do with pregnant patients with acute schizophrenia? If there is a good treatment response, and the patient restores their social function, the possibility of pregnancy becomes realistic. However, safer new agents cannot be used in this category of patients.

In this Special Issue, the following topics will be addressed: new knowledge regarding the origin of schizophrenic symptoms; new targets for psychopharmacological agents; data on the role of oxidative stress, imbalance of the immune system, and inflammation and distortion of microbiota in the origin of schizophrenia.



mdpi.com/si/169797

Special Issue